Business
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
JACKSONVILLE, Fla., March 12, 2026--Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
About this update from Johnson & Johnson
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2690,"height":510,"url":"https://media.zenfs.com/en/business-wire.com/99bc867b4b60e79198ab88ff09bed10f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PWm.Pozk_J54sxiwr_38xw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE4MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/99bc867b4b60e79198ab88ff09bed10f","width":960,"height":182},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/nspYis1FdEUwisFCJsiTkA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/99bc867b4b60e79198ab88ff09bed10f","width":1200,"height":228}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"97% of patients reported no very bothersome visual disturbances, like halos or glare, with TECNIS PureSee IOL1","length":110,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"97% of patients would recommend this IOL to friends or family2","length":62,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"TECNIS PureSee IOL is the first and only U.S. FDA-approved extended depth of focus (EDOF) IOL maintaining contrast sensitivity comparable to an aspheric monofocal IOL1*","length":168,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":340,"olType":false},{"type":"text","content":"JACKSONVILLE, Fla., March 12, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract surgery.1 TECNIS PureSee IOL delivers clarity of vision for patients, with 97% of them reporting no very bothersome visual disturbances.1 TECNIS PureSee IOL will be available for patients in the U.S. later this year.","length":471,"tagName":"p"},{"type":"text","content":""Today marks an exciting milestone for people living with cataracts. The approval of the TECNIS PureSee IOL gives surgeons an important new lens option, reflecting our deep commitment to innovation that delivers high patient satisfaction and supports vision solutions tailored to individual lifestyle needs," said Peter Menziuso, Company Group Chairman, Vision, Johnson & Johnson. "Cataract surgery is often a once-...